Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions
American Journal of Health-System Pharmacy · 11.06.2025 · 82 (12) · 644-659
DOI: 10.1093/ajhp/zxae317 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Health-System Pharmacy, online erschienen am 18.11.2024. Verfasst von Wendy L St Peter und 25 weiteren Autor:innen. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Creatinine, Clinical Decision-Making, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
Purpose
The goals of this paper are to (1) provide evidence and expert consensus to support a unified approach to estimating kidney filtration in adults with stable kidney function using race-free estimated glomerular filtration rate (eGFR) in place of Cockcroft-Gault estimated creatinine clearance (C-G eCrCL) for medical and medication-related decisions, and (2) demonstrate how adjusting eGFR results for an individual’s body surface area (BSA) when it is higher or lower than 1.73 m2 will improve results for medication-related decisions. Summary C-G eCrCL is predominantly used by US pharmacists to determine eGFR for the purposes of medication-related decisions, even though more accurate eGFR equations exist. Several driving factors make it the ideal time to shift clinical practice from using C-G eCrCL to eGFR. These factors include the following: (1) 2024 Food and Drug Administration (FDA) guidance for industry recommends eGFR over C-G eCrCL to evaluate the impact on pharmacokinetics in patients with impaired kidney function; (2) a joint National Kidney Foundation (NKF) and American Society of Nephrology task force recommends 3 race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) eGFR equations for medical and medication-related decision-making; (3) the almost ubiquitous use of standardized serum creatinine assay methods in US clinical laboratories; and (4) increasing availability and use of serum cystatin C for eGFR assessment. This publication guides practitioners through the rationale for using race-free eGFR equations for medication-related decisions and how to implement this practice change.
Conclusion
The NKF Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions suggests that health systems, health settings, clinical laboratories, electronic health record systems, compendia and data vendors, and healthcare practitioners involved with medication-related decision-making transition away from C-G eCrCL and towards the race-free eGFR equations for more accurate assessment of kidney filtration and consistency in medication and medical decision-making across the US.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Zitieren
APA
St Peter, W. L., Bzowyckyj, A. S., Anderson-Haag, T., Awdishu, L., Blackman, M., Bland, A., Chan, E., Chmielewski, C., Delgado, C., Eyler, R., Foster, C., Hudson, J., Kane-Gill, S. L., Kliethermes, M. A., Le, T., Madabushi, R., Martin, B., Miller, W. G., Neumiller, J. J., …, & National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions (2025). Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions. American Journal of Health-System Pharmacy, 82(12), 644-659. https://doi.org/10.1093/ajhp/zxae317
Vancouver
St Peter WL, Bzowyckyj AS, Anderson-Haag T, Awdishu L, Blackman M, Bland A, et al. Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions. American Journal of Health-System Pharmacy. 2025;82(12):644-659. doi:10.1093/ajhp/zxae317
BibTeX
@article{StPeter2025,
author = {St Peter, Wendy L and Bzowyckyj, Andrew S and Anderson-Haag, Tracy and Awdishu, Linda and Blackman, Michael and Bland, Andrew and Chan, Ethan and Chmielewski, Christine and Delgado, Cynthia and Eyler, Rachel and Foster, Charles and Hudson, Joanna and Kane-Gill, Sandra L and Kliethermes, Mary Ann and Le, Tuan and Madabushi, Rajanikanth and Martin, Brianna and Miller, W Greg and Neumiller, Joshua J and Philbrick, Ann M and Roberts, Glenda and Schandorf, Venita and Webb, Andrew J and Wu, Dennis and Nolin, Thomas D and National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions, National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions},
title = {Moving forward from Cockcroft-Gault creatinine clearance to race-free estimated glomerular filtration rate to improve medication-related decision-making in adults across healthcare settings: A consensus of the National Kidney Foundation Workgroup for Implementation of Race-Free eGFR-Based Medication-Related Decisions},
journal = {American Journal of Health-System Pharmacy},
year = {2025},
volume = {82},
number = {12},
pages = {644--659},
doi = {10.1093/ajhp/zxae317}
}
EUVIMED